3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Lymphoma, Non-Hodgkin
4
Lymphoma, Follicular
3
Hodgkin Disease
3
Multiple Myeloma
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Recurrence
1
Neoplasms by Site
1
Neoplasms
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia
1
Carcinoma, Renal Cell
1
Bronchiolitis Obliterans Syndrome
1
Interventions
Rituximab
30
ibrutinib
26
Bendamustine Hydrochloride
18
Cyclophosphamide
17
acalabrutinib
14
fludarabine
13
Lenalidomide
11
zanubrutinib
10
venetoclax
9
Vincristine
7
Bortezomib
7
pirtobrutinib
5
brexucabtagene autoleucel
5
Prednisone
5
Doxorubicin
5
temsirolimus
4
parsaclisib
4
aflibercept
4
Gemcitabine
4
ublituximab
3
orelabrutinib
3
loncastuximab tesirine
3
idelalisib
3
ibritumomab tiuxetan
3
Sensitivity and Specificity
3
Antigens, CD19
3
tositumomab I-131
2
tazemetostat
2
pembrolizumab
2
fludarabine phosphate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, Mantle-Cell
×
abexinostat
×
Clear all
NCT00724984
2014-04-07
PCYC-0403
Pharmacyclics LLC.
Phase 1/2
Completed
55 enrolled
11 charts